Bank of America
CABA icon

Bank of America’s Cabaletta Bio CABA Stock Holding History

Bank of America’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
493,314
+224,057
+83% +$737K ﹤0.01% 4383
2026
Q1 		$724K Buy
269,257
+254,865
+1,771% +$708K ﹤0.01% 4698
2025
Q4 		$31.5K Sell
14,392
-253,666
-95% -$629K ﹤0.01% 5957
2025
Q3 		$627K Sell
268,058
-230,185
-46% -$395K ﹤0.01% 5644
2025
Q2 		$757K Sell
498,243
-485,852
-49% -$758K ﹤0.01% 5470
2025
Q1 		$1.36M Buy
984,095
+437,634
+80% +$932K ﹤0.01% 5004
2024
Q4 		$1.24M Buy
546,461
+67,787
+14% +$238K ﹤0.01% 4841
2024
Q3 		$2.26M Buy
478,674
+309,569
+183% +$1.79M ﹤0.01% 4463
2024
Q2 		$1.26M Sell
169,105
-68,998
-29% -$846K ﹤0.01% 4751
2024
Q1 		$4.06M Buy
238,103
+77,583
+48% +$1.67M ﹤0.01% 3811
2023
Q4 		$3.64M Buy
160,520
+19,334
+14% +$325K ﹤0.01% 3814
2023
Q3 		$2.15M Buy
141,186
+115,688
+454% +$1.58M ﹤0.01% 4181
2023
Q2 		$329K Buy
25,498
+16,647
+188% +$181K ﹤0.01% 5528
2023
Q1 		$73.2K Buy
8,851
+7,626
+623% +$71.4K ﹤0.01% 6369
2022
Q4 		$11.3K Sell
1,225
-7,969
-87% -$29K ﹤0.01% 6887
2022
Q3 		$6K Sell
9,194
-6,053
-40% -$7.29K ﹤0.01% 7335
2022
Q2 		$16K Sell
15,247
-17,132
-53% -$24.2K ﹤0.01% 7239
2022
Q1 		$66K Buy
32,379
+25,268
+355% +$66.1K ﹤0.01% 7047
2021
Q4 		$27K Sell
7,111
-7,396
-51% -$78.9K ﹤0.01% 7429
2021
Q3 		$176K Sell
14,507
-5,698
-28% -$52.5K ﹤0.01% 6386
2021
Q2 		$174K Buy
20,205
+10,227
+102% +$100K ﹤0.01% 6186
2021
Q1 		$111K Buy
9,978
+6,808
+215% +$83.2K ﹤0.01% 6342
2020
Q4 		$40K Sell
3,170
-895
-22% -$11.6K ﹤0.01% 6400
2020
Q3 		$44K Sell
4,065
-2,594
-39% -$29.8K ﹤0.01% 6058
2020
Q2 		$75K Buy
6,659
+3,317
+99% +$25.4K ﹤0.01% 5803
2020
Q1 		$25K Buy
3,342
+2,207
+194% +$30.3K ﹤0.01% 6097
2019
Q4 		$16K Buy
+1,135
New +$13.4K ﹤0.01% 6543

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bank of America's CABA Position: Q2 2026 in Review

Bank of America increased its Cabaletta Bio (CABA) stake by 83% in Q2 2026, buying an estimated $737K and bringing the position to 493,314 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #4383.

Bank of America first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.06M in Q1 2024. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Bank of America held 493,314 shares of Cabaletta Bio worth $1.53M as of Q2 2026.
  • Bank of America bought 224,057 Cabaletta Bio shares in Q2 2026, an estimated $737K.
  • Cabaletta Bio made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4383 holding.
  • Bank of America first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • Bank of America's Cabaletta Bio position peaked at $4.06M in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.